Surrogate Parameters, Instead of the Genetic Profile, for Recurrence Risk Evaluation in #x201C;Early-Stage Breast Cancer Cases#x201D; in a Middle #x2013; Income Country like Argentina

Abstract

Breast Cancer (BC) is the most commonly diagnosed cancer amongst women worldwide and is a leading cause of death and disability among women in lowand middleincome countries (MICs) among which is Argentina. Nowadays in BC, beyond the standard determination of cancer stage according to the classic anatomical criteria of the TNM the study of genic profile (GP) of cancer has also been encouraged. Implementation of the multigene panels assay has led to a change in the manner in which chemotherapy is utilized mainly in patients with, early stage, estrogen receptor (ER)-positive, Her2-neu negative, lymph nodenegative BC ensuring that patients at highest risk of recurrence are prescribed systemic treatment, while at the same time sparing low-risk patients potential adverse events from therapy unlikely to influence their survival. Multigene panels can provide better risk discrimination relative to clinic-pathological factors. Unfortunately, all these tests are expensive.